The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28—Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women. The authors, that include Professor Paul Franks, Lund University, Helsingborg Hospital, Helsingborg, Sweden and Professor Claire Meek, Leicester Diabetes Research Centre and Leicester NIHR Biomedical Research Centre, Leicester, UK and colleagues, issue a call to action to improve the evidence based across the board for GLP-1 RA use in women worldwide.
❓ Unknown
Critical Research Gaps in GLP-1 RA Drug Use Among Women Highlighted at EASD Meeting
Oct 1, 2026
October 1, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
A recent study presented at the EASD Annual Meeting highlights the critical need for improved research on GLP-1 RA drug use among women, led by experts from Sweden and the UK. This call to action emphasizes the importance of addressing gender-specific health issues globally, including in Iran, where women's health is a significant concern.
🔍 Quick Context Guide
💡 Bottom Line:
The call for more research on GLP-1 RA drug use among women is crucial for improving health outcomes globally, including in Iran.
👥 Key Players
Professor Paul Franks
MENTIONED
Lead researcher from Lund University
"His research focuses on diabetes and women's health, which is critical in addressing health disparities in Iran."
Professor Claire Meek
MENTIONED
Lead researcher from Leicester Diabetes Research Centre
"Her work emphasizes the importance of gender-specific health research, relevant for improving women's health outcomes in Iran."
📰 What Happened
At the EASD Annual Meeting, researchers presented a study highlighting the need for more research on GLP-1 RA drug use among women. They called for improved evidence-based practices to address gender-specific health issues.
- GLP-1 RA drugs are used for managing diabetes and obesity.
- The study emphasizes a significant gap in research regarding their effects on women.
💡 Why It Matters
🇮🇷 For Iran: Improving research on women's health issues can lead to better healthcare policies and practices in Iran, where women's health is a critical concern.
🌍 Regional: Addressing gender-specific health issues can improve overall health outcomes in the Middle East, where similar disparities exist.
🌐 International: Highlighting the need for gender-specific research can influence global health policies and funding priorities.
📚 Background
GLP-1 RA drugs are increasingly used in diabetes treatment, but there is a lack of research on their effects specifically in women, which can lead to inadequate healthcare solutions.
Women's health
Diabetes management
📡 Source:
NEUTRAL
📊 Confidence:
70%
The article is based on research presented at a reputable medical conference and published in a peer-reviewed journal, indicating a high level of reliability.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Davoud Rokhbin Executed for Murder in Kashan Prison
Just now •
Ali Mokhtari Executed for Rape in Shahre Kord
Just now •
Trump: I Will Not Hesitate to Launch a New Attack on Iran if Necessary
7 min ago •
Key Protein TRF2 Essential for Muscle Repair and Regeneration
16 min ago •